Proteins and Peptides

19 June 2025

Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

16 June 2025

D&D Pharmatech Announces Positive Phase 2 Results for DD01 in MASH with Robust Reductions in Liver Fat Accompanied by Improvements in Liver and Metabolic Health

16 June 2025

Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions

16 June 2025

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

13 June 2025

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

12 June 2025

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

12 June 2025

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

12 June 2025

Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025

12 June 2025

Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH

10 June 2025

XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology

9 June 2025

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

6 June 2025

Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases

5 June 2025

Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in Phase 3 Study of ELGN-2112 for Treatment of Intestinal Malabsorption in Preterm Infants

5 June 2025

EphA2 targeting PDC drug SC-102 received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA)

5 June 2025

Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Germany

3 June 2025

FDA Accepts TransCon® CNP NDA for Priority Review

3 June 2025

Bitterroot Bio Announces Dosing of First Patient in MATADOR Phase 2a Study of BRB-002, an Immunomodulating Therapy Targeting CD47 in Atherosclerotic Cardiovascular Disease

3 June 2025

Sapience Therapeutics Provides Data Update from Phase 2 Trial of Lucicebtide in Patients with Glioblastoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

3 June 2025

NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury

2 June 2025

Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome

2 June 2025

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

1 June 2025

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

31 May 2025

Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)

31 May 2025

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

30 May 2025

First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT

29 May 2025

Aktis Oncology initiates phase 1b clinical trial of its nectin-4-targeting radiopharmaceutical product candidate, AKY-1189, across multiple tumor types

29 May 2025

ProteinQure Raises Series A Financing to Advance First AI-Designed Peptide Therapeutic into Clinical Trials

28 May 2025

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

17 May 2025

CANbridge Announces Marketing Approval of Velaglucerase-beta for Injection (Gaurunning), a Class 1 New Drug for Treating Type I and III Gaucher Disease, in China

16 May 2025

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

PD-1 Agonists Pipeline Review

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

B7-H4 Targeted Antibody Therapy Pipeline Review

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

Aflibercept (Eylea) Biosimilars Pipeline Review